Zydus Life Science , a leading global pharmaceutical company, has reported robust financial results for the second quarter of fiscal year 2026, demonstrating strong growth across key business segments and reaffirming its commitment to future expansion. The company has also received tentative approval from the USFDA for Olaparib tablets, marking another milestone in its product portfolio.

Financial Highlights

For Q2 FY26, Zydus Lifesciences reported:

• Revenue from operations of ₹61,232.00 million, up 17% year-over-year
• EBITDA of ₹20,158.00 million, a significant increase of 38% year-over-year
• EBITDA margin of 32.9%, improving by 500 basis points from the previous year
• Net profit of ₹12,586.00 million, up 38% year-over-year

Segment Performance

The company's US formulations business continued its strong performance, registering revenues of ₹27,437.00 million, up 13.5% year-over-year. During the quarter, Zydus Lifesciences launched seven new products in the US market and received approval for four ANDAs, including one tentative approval.

India formulations business grew by 8.4% year-over-year, outpacing the Indian Pharmaceutical Market (IPM) growth. The company maintained its leadership position in key therapies such as Cardiology, Gynecology, and Oncology.

The Consumer Wellness segment showed remarkable growth of 30.7% year-over-year, bolstered by the recent acquisition of UK-based Comfort Click Limited (CCL), marking Zydus Lifesciences's first international acquisition in the wellness space.

International Markets formulations business demonstrated exceptional growth of 39.4% year-over-year, driven by strong demand and focused execution across regions.

Strategic Developments

Zydus Lifesciences management expects to achieve their targeted top-line growth and profitability for FY26. The company maintains its guidance of 26%+ EBITDA margin for the full year, despite lower margins from recent acquisitions like Comfort Click.

In a significant development, Zydus Lifesciences reported positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial of Saroglitazar Magnesium for Primary Biliary Cholangitis (PBC) in the US market. The company is preparing to file a New Drug Application (NDA) with the USFDA in Q4 FY26.

Additionally, Zydus Lifesciences received regulatory approval to initiate Phase II clinical trials of Bivalent Typhoid Conjugate Vaccine in India, further strengthening its vaccine portfolio.

Expansion and Acquisitions

The company completed the acquisition of Amplitude Surgical SA, France, enhancing its presence in the medical devices sector. Zydus Lifesciences now holds 100% of Amplitude's share capital, following a successful tender offer and subsequent delisting from Euronext Paris.

In the Consumer Wellness segment, Zydus Lifesciences acquired Comfort Click Limited, a fast-growing digital consumer healthcare platform specializing in vitamins, minerals, and supplements (VMS). This acquisition is expected to significantly strengthen Zydus Lifesciences's international presence in key markets across the UK, EU, and US.

Regulatory Milestone

In a recent development, Zydus Lifesciences has received tentative approval from the USFDA for Olaparib tablets in 100 mg and 150 mg dosages. This regulatory milestone allows the pharmaceutical company to potentially market these cancer treatment tablets in the US market pending final approval conditions.

Outlook

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, commented on the results: "Our strong performance this quarter reaffirms the power of our diversified business model and our execution capabilities across geographies and verticals. We delivered robust revenue growth and industry-leading profitability, aided by consistent outperformance in our US and India formulations businesses, sustained high growth in International Markets as well as strategic acquisitions in Wellness and MedTech."

As Zydus Lifesciences continues to expand its global footprint and diversify its product portfolio, the company remains well-positioned to capitalize on growth opportunities in the pharmaceutical and wellness sectors. The management's commitment to maintaining strong EBITDA margins and focus on strategic acquisitions suggests a positive outlook for the company's future performance.

Zydus Life Science , a leading global pharmaceutical company, has reported significant progress on multiple fronts. The company announced a 13.5% growth in its US formulations business, outpacing its full-year US business growth which was in single digits. This growth demonstrates the company's strengthening position in the crucial US market.

In addition to its financial performance, Zydus has achieved a significant milestone in its quest to address rare diseases. The company recently announced that its novel oral treatment, Desidustat, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of beta-thalassemia.

Understanding the Designation

The Orphan Drug Designation is a special status granted by the FDA to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States. This designation brings with it several benefits for Zydus Lifesciences:

• Market Exclusivity: Upon FDA approval, Zydus may be eligible for seven years of market exclusivity for Desidustat in the treatment of beta-thalassemia.
• Financial Incentives: The company could benefit from tax credits for qualified clinical testing and prescription drug user fee exemptions.
• Development Support: The designation provides access to certain development incentives, potentially accelerating the drug's path to market.

Desidustat: A Promising Treatment

Desidustat is a hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) that shows promise in increasing hemoglobin and red blood cell counts. For patients with beta-thalassemia, who often suffer from low hemoglobin levels and require lifelong blood transfusions, this treatment could be transformative.

Impact on Beta-Thalassemia Patients

Beta-thalassemia is a genetic blood disorder characterized by reduced or absent production of hemoglobin. Patients with this condition often experience:

• Weakness and fatigue
• Complications due to lack of oxygen in body tissues
• Need for chronic blood transfusions
• Risk of iron overload from frequent transfusions

Desidustat's potential to increase hemoglobin and red blood cell production could significantly improve the quality of life for these patients, potentially reducing their dependence on blood transfusions.

Zydus's Commitment to Innovation

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, emphasized the significance of this development: "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop Desidustat to address beta-thalassemia."

This achievement aligns with Zydus's mission to empower people with the freedom to live healthier and more fulfilled lives. The company's focus on developing innovative, first-in-class products for unmet healthcare needs continues to drive its research and development efforts.

Looking Ahead

While the Orphan Drug Designation is a crucial step forward, it's important to note that Desidustat still needs to complete clinical trials and receive FDA approval before it can be marketed for beta-thalassemia treatment in the United States. However, this designation provides a clear pathway and support for Zydus to continue its development efforts.

As the pharmaceutical landscape evolves, Zydus Lifesciences' progress with Desidustat represents a beacon of hope for beta-thalassemia patients and a testament to the company's commitment to addressing rare diseases through innovative therapies. Coupled with its strong performance in the US formulations business, Zydus is demonstrating growth and innovation across multiple areas of its operations.